Drug-drug interactions (DDIs) arise when multiple drugs are administered concurrently. Accurately predicting the specific mechanisms underlying DDIs (named DDI events or DDIEs) is critical for the safe clinical use of drugs. DDIEs are typically represented as textual descriptions. However, most computational methods focus more on predicting the DDIE class label over generating human-readable natural language increasing clinicians’ interpretation costs. Furthermore, current methods overlook the fact that each drug assumes distinct biological functions in a DDI, which, when used as input context, can enhance the understanding of the DDIE process and benefit DDIE generation by the language model (LM). In this work, we propose a novel pairwise knowledge-augmented generative method (termed PKAG-DDI) for DDIE text generation. It consists of a pairwise knowledge selector efficiently injecting structural information between drugs bidirectionally and simultaneously to select pairwise biological functions from the knowledge set, and a pairwise knowledge integration strategy that matches and integrates the selected biological functions into the LM. Experiments on two professional datasets show that PKAG-DDI outperforms existing methods in DDIE text generation, especially in challenging inductive scenarios, indicating its practicality and generalization.

Using computational methods to personalize drug response prediction holds great promise to improve cancer therapy. Most existing methods use either biochemical information or response-related networks to predict drug response, nevertheless, the information they considered is not comprehensive. In this study, we present a novel end-to-end deep learning-based method Graph Neural Network with multi-task learning for Drug Response Prediction (GNNDRP). It leverages biochemical features as well as the hidden features from the heterogeneous network which incorporates the known drug-cell line responses, drug similarities, and cell line similarities, to complete the drug response prediction task. Moreover, GNNDRP designs a self-supervised task to enhance the representation capacity from the response network and further improve the model prediction performance. Extensive experiments show that GNNDRP outperforms existing state-of-the-art prediction methods under various experimental settings. The ablation analysis reveals that the biochemical characteristics, response-related network, and our self-supervised strategy can boost the predictive power. Additionally, case studies further validate the effectiveness of GNNDRP in identifying novel drug-cell line responses.

Therapeutic peptides represent a unique class of pharmaceutical agents crucial for the treatment of human diseases. Recently, deep generative models have exhibited remarkable potential for generating therapeutic peptides, but they only utilize sequence or structure information alone, which hinders the performance in generation. In this study, we propose a Multi-Modal Contrastive Diffusion model (MMCD), fusing both sequence and structure modalities in a diffusion framework to co-generate novel peptide sequences and structures. Specifically, MMCD constructs the sequence-modal and structure-modal diffusion models, respectively, and devises a multi-modal contrastive learning strategy with inter-contrastive and intra-contrastive in each diffusion timestep, aiming to capture the consistency between two modalities and boost model performance. The inter-contrastive aligns sequences and structures of peptides by maximizing the agreement of their embeddings, while the intra-contrastive differentiates therapeutic and non-therapeutic peptides by maximizing the disagreement of their sequence/structure embeddings simultaneously. The extensive experiments demonstrate that MMCD performs better than other state-of-the-art deep generative methods in generating therapeutic peptides across various metrics, including antimicrobial/anticancer score, diversity, and peptide-docking.

Drug-drug interactions (DDIs) could lead to various unexpected adverse consequences, so-called DDI events. Predicting DDI events can reduce the potential risk of combinatorial therapy and improve the safety of medication use, and has attracted much attention in the deep learning community. Recently, graph neural network (GNN)-based models have aroused broad interest and achieved satisfactory results in the DDI event prediction. Most existing GNN-based models ignore either drug structural information or drug interactive information, but both aspects of information are important for DDI event prediction. Furthermore, accurately predicting rare DDI events is hindered by their inadequate labeled instances. In this paper, we propose a new method, Multi-Relational Contrastive learning Graph Neural Network, MRCGNN for brevity, to predict DDI events. Specifically, MRCGNN integrates the two aspects of information by deploying a GNN on the multi-relational DDI event graph attributed with the drug features extracted from drug molecular graphs. Moreover, we implement a multi-relational graph contrastive learning with a designed dual-view negative counterpart augmentation strategy, to capture implicit information about rare DDI events. Extensive experiments on two datasets show that MRCGNN outperforms the state-of-the-art methods. Besides, we observe that MRCGNN achieves satisfactory performance when predicting rare DDI events.

Identifying the potential associations among drugs, microbes and diseases is of great significance in exploring the pathogenesis and improving precision medicine. There are plenty of computational methods for pair-wise association prediction, such as drug-microbe and microbe-disease associations, but few methods focus on the higher-order triple-wise drug-microbe-disease (DMD) associations. Driven by the advancement of hypergraph neural networks (HGNNs), we expect them to fully capture high-order interaction patterns behind the hypergraph formulated by DMD associations and realize sound prediction performance. However, the confirmed DMD associations are insufficient due to the high cost of in vitro screening, which forms a sparse DMD hypergraph and thus brings in suboptimal generalization ability. To mitigate the limitation, we propose a Multi-view Contrastive Learning Hypergraph Neural Network, named MCHNN, for DMD association prediction. We design a novel multi-view contrastive learning on the DMD hypergraph as an auxiliary task, which guides the HGNN to learn more discriminative representations and enhances the generalization ability. Extensive computational experiments show that MCHNN achieves satisfactory performance in DMD association prediction and, more importantly, demonstrate the effectiveness of our devised multi-view contrastive learning on the sparse DMD hypergraph.

Exploring the transcriptional response after employing chemical compounds assists in treating gene-related diseases and understanding biological activity of compounds. Calculating the similarity of drug transcriptional response can help to discover novel compounds that have the similar biological activity to known drugs for treating the same disease. Considering the transcriptional profiles of compounds are limited and harder to get than the structure of compounds, it is worth modeling the structure-transcriptional response similarity relationship. In this paper, we propose a signed graph convolutional network (SGCN)-based method, namely SGCN-DTRS, to predict drug transcriptional response similarity, which is quantitatively measured by Connectivity Map (CMap) scores, from their structures. SGCNDTRS constructs a CMap signed network from compounds and their CMap scores in the training data, which takes compounds as nodes, molecular structural representations of compounds as the attributes of nodes, and similarity relations between compounds as edges. Then SGCN-DTRS learns the CMap compound embeddings to predict CMap scores of pairwise compounds. Extensive experiments verify the superiority of the proposed method against the compared state-of-the-art methods and reveal that the relational information of the CMap data, which is learned from CMap signed network, is important for the CMap score prediction. SGCN-DTRS can not only work for the compounds in the training set but also is applicable to unseen compounds.

Predicting drug-target interactions (DTIs) is crucial at many phases of drug discovery and repositioning. Many computational methods based on heterogeneous networks (HNs) have proved their potential to predict DTIs by capturing extensive biological knowledge and semantic information from meta-paths. However, existing methods manually customize meta-paths, which is overly dependent on some specific expertise. Such strategy heavily limits the scalability and flexibility of these models, and even affects their predictive performance. To alleviate this limitation, we propose a novel HN-based method with attentive meta-path extraction for DTI prediction, named HampDTI, which is capable of automatically extracting useful meta-paths through a learnable attention mechanism instead of pre-definition based on domain knowledge. Specifically, by scoring multi-hop connections across various relations in the HN with each relation assigned an attention weight, HampDTI constructs a new trainable graph structure, called meta-path graph. Such meta-path graph implicitly measures the importance of every possible meta-path between drugs and targets. To enable HampDTI to extract more diverse meta-paths, we adopt a multi-channel mechanism to generate multiple meta-path graphs. Then, a graph neural network is deployed on the generated meta-path graphs to yield the multi-channel embeddings of drugs and targets. Finally, HampDTI fuses all embeddings from different channels for predicting DTIs. The meta-path graphs are optimized along with the model training such that HampDTI can adaptively extract valuable meta-paths for DTI prediction. The experiments on benchmark datasets not only show the superiority of HampDTI in DTI prediction over several baseline methods, but also, more importantly, demonstrate the effectiveness of the model discovering important meta-paths.

Drug repositioning/repurposing is a very important approach towards identifying novel treatments for diseases in drug discovery. Recently, large-scale biological datasets are increasingly available for pharmaceutical research and promote the development of drug repositioning, but efficiently utilizing these datasets remains challenging. In this paper, we develop a novel multimodal framework, termed GraphPK (Graph-based Prior Knowledge) for improving in silico drug repositioning via using the prior knowledge from a drug knowledge graph. First, we construct a knowledge graph by integrating relevant bio-entities (drugs, diseases, etc.) and associations/interactions among them, and apply the knowledge graph embedding technique to extract prior knowledge of drugs and diseases. Moreover, we make use of the known drug-disease association, and obtain known association-based features from an association bipartite graph through graph embedding, and also take into account biological domain features, i.e., drug chemical structures and disease semantic similarity. Finally, we design a multimodal neural network to combine three types of features from the knowledge graph, the known associations and the biological domain, and build the prediction model for predicting drug-disease associations. Massive experiments show that our method outperforms other state-of-the-art methods in terms of most metrics, and the ablation analysis regarding the three types of features reveals that prior knowledge from knowledge graphs can not only lift the predictive power of in silico drug repositioning, but also enhance the model's robustness to different scenarios. The results of case studies offer support that GraphPK has the potential for actual use.

MicroRNAs (miRNAs) play crucial roles in multifarious biological processes associated with human diseases. Identifying potential miRNA-disease associations contributes to understanding the molecular mechanisms of miRNA-related diseases. Most of the existing computational methods mainly focus on predicting whether a miRNA-disease association exists or not. However, the roles of miRNAs in diseases are prominently diverged, for instance, Genetic variants of miRNA (mir-15) may affect the expression level of miRNAs leading to B cell chronic lymphocytic leukemia, while circulating miRNAs (including mir-1246, mir-1307-3p, etc.) have potentials to detecting breast cancer in the early stage. In this paper, we aim to predict multi-type miRNA-disease associations instead of taking them as binary. To this end, we innovatively represent miRNA-disease-type triples as a tensor and introduce tensor decomposition methods to solve the prediction task. Experimental results on two widely-adopted miRNA-disease datasets: HMDD v2.0 and HMDD v3.2 show that tensor decomposition methods improve a recent baseline in a large scale (up to $38\%$ in Top-1F1). We then propose a novel method, Tensor Decomposition with Relational Constraints (TDRC), which incorporates biological features as relational constraints to further the existing tensor decomposition methods. Compared with two existing tensor decomposition methods, TDRC can produce better performance while being more efficient.